 |
| |
| |
| |
| |
| |
| |
|
| TissGeneSummary for SUZ12 |
 Gene summary |
| Basic gene information | Gene symbol | SUZ12 |
| Gene name | SUZ12 polycomb repressive complex 2 subunit | |
| Synonyms | CHET9|JJAZ1 | |
| Cytomap | UCSC genome browser: 17q11.2 | |
| Type of gene | protein-coding | |
| RefGenes | NM_015355.2, | |
| Description | chET 9 proteinchromatin precipitated E2F target 9 proteinjoined to JAZF1 proteinpolycomb protein SUZ12suppressor of zeste 12 homologsuppressor of zeste 12 protein homolog | |
| Modification date | 20141222 | |
| dbXrefs | MIM : 606245 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000178691 | ||
| HPRD : 06949 | ||
| Vega : OTTHUMG00000132813 | ||
| Protein | UniProt: go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_SUZ12 | |
| BioGPS: 23512 | ||
| Pathway | NCI Pathway Interaction Database: SUZ12 | |
| KEGG: SUZ12 | ||
| REACTOME: SUZ12 | ||
| Pathway Commons: SUZ12 | ||
| Context | iHOP: SUZ12 | |
| ligand binding site mutation search in PubMed: SUZ12 | ||
| UCL Cancer Institute: SUZ12 | ||
| Assigned class in TissGDB* | C | |
| Included tissue-specific gene expression resources | TiGER,GTEx | |
| Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Bone marrowTestis | |
| Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | LAMLTGCT | |
| Reference showing the relevant tissue of SUZ12 | ||
| Description by TissGene annotations | Cancer gene Have significant anti-correlated miRNA TissgsLTS Fused withTSGene | |
| * Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO term | PubMed ID |
| Top |
| TissGeneExp for SUZ12 |
| Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
 |
| Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
 |
| Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| - Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
| Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
| Top |
| TissGene-miRNA for SUZ12 |
| Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
| Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
| LUAD | hsa-miR-186-5p | MIMAT0000456 | 0.041 | -0.27 | 60 |
| THYM | hsa-miR-520a-3p | MIMAT0002834 | 0.0033 | -0.27 | 122 |
| THYM | hsa-miR-520e | MIMAT0002825 | 0.012 | -0.28 | 122 |
| LUAD | hsa-miR-16-5p | MIMAT0000069 | 0.027 | -0.29 | 60 |
| THYM | hsa-miR-520d-3p | MIMAT0002856 | 0.0017 | -0.3 | 122 |
| LUAD | hsa-miR-195-5p | MIMAT0000461 | 0.0098 | -0.33 | 60 |
| Top |
| TissGeneMut for SUZ12 |
| TissGeneSNV for SUZ12 |
| nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
 |
 |
| Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
 |
| - nsSNVs sorted by frequency. |
| AAchange | Cancer type | # samples |
| p.Q387R | LIHC | 1 |
| p.A332T | STAD | 1 |
| p.D665Y | UCEC | 1 |
| p.D725Y | UCEC | 1 |
| p.K223* | KIRC | 1 |
| p.S604C | BLCA | 1 |
| p.E421K | GBM | 1 |
| p.Q441H | UCEC | 1 |
| p.E347K | READ | 1 |
| p.L529V | BRCA | 1 |
| p.E601Q | BLCA | 1 |
| p.K223X | KIRC | 1 |
| p.N216H | UCEC | 1 |
| p.A401V | LIHC | 1 |
| p.C325Y | UCEC | 1 |
| p.P207S | SKCM | 1 |
| p.R458H | ESCA | 1 |
| p.A332V | LUSC | 1 |
| p.E364* | LUSC | 1 |
| p.E142D | UCEC | 1 |
| p.R101Q | UCEC | 1 |
| p.L377F | BLCA | 1 |
| p.V581E | OV | 1 |
| p.Q221* | BLCA | 1 |
| p.I491V | LIHC | 1 |
| p.P228T | THYM | 1 |
| p.R286Q | STAD | 1 |
| p.G163D | LAML | 1 |
| p.N477T | KIRC | 1 |
| p.I671M | UCEC | 1 |
| p.H471R | COAD | 1 |
| p.D290N | SKCM | 1 |
| p.Q95H | BRCA | 1 |
| p.R458H | LUSC | 1 |
| p.S233F | SKCM | 1 |
| p.K521E | BLCA | 1 |
| p.R682C | UCEC | 1 |
| p.F432C | UCEC | 1 |
| p.K459E | LUSC | 1 |
| p.R575C | STAD | 1 |
| p.R103Q | LAML | 1 |
| p.K143E | COAD | 1 |
| p.M265I | BLCA | 1 |
| p.Y480C | HNSC | 1 |
| p.Q80H | THYM | 1 |
| p.E388X | KIRP | 1 |
| p.K650N | COAD | 1 |
| p.R439M | UCEC | 1 |
| p.S693F | BLCA | 1 |
| p.H620R | KIRP | 1 |
| p.K468N | HNSC | 1 |
| p.R286* | LGG | 1 |
| p.L338H | KIRC | 1 |
| p.E383K | BRCA | 1 |
| p.S583I | BLCA | 1 |
| Top |
| TissGeneCNV for SUZ12 |
| Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
 |
| Top |
| TissGeneFusions for SUZ12 |
| Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
| Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
| Chimerdb3.0 | ChiTaRs | NA | AW369467 | SUZ12-SUZ12 | chr17:30320303 | chr17:30310084 | |
| Chimerdb3.0 | FusionScan | LGG | TCGA-DU-5874-01A | SUZ12-LRRC37A2 | CDS-5'UTR | chr17:30303633 | chr17:44623620 |
| Chimerdb3.0 | FusionScan | LGG | TCGA-DU-5874-01A | SUZ12-LRRC37A | CDS-5'UTR | chr17:30303633 | chr17:44405757 |
| Chimerdb3.0 | FusionScan | BRCA | TCGA-A2-A0YT-01A | SUZ12-IARS | In-Frame | chr17:30264539 | chr9:94985771 |
| Chimerdb3.0 | FusionScan | BRCA | TCGA-BH-A18R-01A | SUZ12-USP32 | Out-of-Frame | chr17:30264539 | chr17:58332619 |
| Top |
| TissGeneNet for SUZ12 |
| Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
| BRCA (tumor) | BRCA (normal) |
| SUZ12, RBL2, USP7, CREB1, E2F4, CTCF, SIRT1, RBBP4, AEBP2, CBX5, MED17, RB1, RBL1, HIST1H1C, CDK19, EED, KDM5A, HIC1, MTF2, CDYL, JARID2 (tumor) | SUZ12, RELA, RBL2, RELB, USP7, CREB1, E2F4, CDK8, CTCF, PML, SIRT1, RBBP4, AEBP2, CEBPD, CBX5, RBL1, DNMT1, KDM5A, HIC1, PHF1, CDYL (normal) |
 |  |
| COAD (tumor) | COAD (normal) |
| SUZ12, ELAVL1, RELB, HDAC2, CREB1, RBBP7, WDR77, SIRT1, RBBP4, AEBP2, CBX5, MED17, RBL1, H2AFY, HIST1H1C, DNMT1, KDM5A, HIC1, MTF2, SETD8, H2AFY2 (tumor) | SUZ12, ELAVL1, SUMO2, E2F1, RELB, CREB1, CDK8, CTCF, UBE2I, SIRT1, RBBP4, AEBP2, EZH2, RBL1, DNMT1, UHRF1, CTNNA1, EED, HIC1, PHF1, MTF2 (normal) |
 |  |
| HNSC (tumor) | HNSC (normal) |
| SUZ12, RBL2, USP7, CREB1, CDK8, CTCF, RBBP4, AEBP2, EZH2, MED17, RB1, RBL1, HIST1H1C, DNMT1, CDK19, UHRF1, CTNNA1, KDM5A, PHF1, MTF2, JARID2 (tumor) | SUZ12, ELAVL1, RBL2, HDAC2, CREB1, CDK8, CTCF, RBBP7, SIRT1, RBBP4, AEBP2, EZH2, CBX5, RB1, RBL1, DNMT1, PPP1R8, CDK19, UHRF1, KDM5A, MTF2 (normal) |
 |  |
| KICH (tumor) | KICH (normal) |
| SUZ12, ELAVL1, SNAI1, USP7, PJA1, CTCF, EWSR1, RBBP7, WDR77, AEBP2, CBX5, RBL1, H2AFY, DNMT1, PPP1R8, CDK19, CTNNA1, KDM5A, JARID2, EZH1, H2AFY2 (tumor) | SUZ12, ELAVL1, HDAC2, CREB1, E2F4, CDK8, UBE2I, RBBP7, PML, RBBP4, AEBP2, CBX5, MED17, RB1, RBL1, HIST1H1C, CDK19, KDM5A, CDYL, SETD8, H2AFY2 (normal) |
 |  |
| KIRC (tumor) | KIRC (normal) |
| SUZ12, RBL2, HDAC2, USP7, CREB1, CDK8, MED6, SIRT1, RBBP4, AEBP2, CBX5, MED17, RB1, RBL1, CDK19, EED, KDM5A, PHF1, MTF2, CDYL, JARID2 (tumor) | SUZ12, RELA, RBL2, RELB, HDAC2, USP7, CREB1, PJA1, CDK8, CTCF, UBE2I, PML, SIRT1, RBBP4, AEBP2, MED17, RB1, RBL1, HIST1H1C, KDM5A, CDYL (normal) |
 |  |
| KIRP (tumor) | KIRP (normal) |
| SUZ12, RELA, E2F1, RBL2, RELB, SETDB1, CREB1, CTCF, WDR77, PML, SIRT1, AEBP2, CEBPD, RBL1, H2AFY, RARG, CTNNA1, KDM5A, HIC1, PHF1, H2AFY2 (tumor) | SUZ12, RBL2, RELB, HDAC2, VAV1, CREB1, CDK8, CTCF, PML, SIRT1, RBBP4, AEBP2, CEBPD, MED17, RB1, RBL1, DNMT1, CDK19, KDM5A, PHF1, CDYL (normal) |
 |  |
| LIHC (tumor) | LIHC (normal) |
| SUZ12, RELA, RBL2, USP7, CREB1, CDK8, CTCF, WDR77, SIRT1, RBBP4, AEBP2, MED17, RB1, RBL1, HIST1H1C, DNMT1, CDK19, EED, KDM5A, MTF2, CDYL (tumor) | SUZ12, E2F1, SETDB1, CREB1, CDK8, CTCF, SIRT1, RBBP4, AEBP2, EZH2, CEBPD, MED17, RBL1, DNMT1, CDK19, UHRF1, EED, KDM5A, MTF2, CDYL, JARID2 (normal) |
 |  |
| LUAD (tumor) | LUAD (normal) |
| SUZ12, ELAVL1, RELA, E2F1, RBL2, USP7, CREB1, E2F4, PJA1, UBE2I, WDR77, PML, SIRT1, AEBP2, RB1, RBL1, RARG, GATA4, CDK19, KDM5A, MTF2 (tumor) | SUZ12, ELAVL1, E2F1, HDAC2, CREB1, CDK8, CTCF, RBBP7, SIRT1, RBBP4, AEBP2, EZH2, CEBPD, CBX5, RBL1, DNMT1, UHRF1, KDM5A, PHF1, MTF2, JARID2 (normal) |
 |  |
| LUSC (tumor) | LUSC (normal) |
| SUZ12, RBL2, HDAC2, USP7, CREB1, E2F4, CTCF, EWSR1, PML, SIRT1, RBBP4, AEBP2, CEBPD, CBX5, MED17, RB1, RBL1, CDK19, KDM5A, HIC1, MTF2 (tumor) | SUZ12, ELAVL1, SUMO2, E2F1, SETDB1, HDAC2, USP7, CTCF, PML, AEBP2, EZH2, CEBPD, RBL1, DNMT1, GATA4, CDK19, UHRF1, KDM5A, HIC1, PHF1, EZH1 (normal) |
 |  |
| PRAD (tumor) | PRAD (normal) |
| SUZ12, RBL2, HDAC2, CREB1, E2F4, CDK8, SIRT1, RBBP4, CEBPD, MED17, RB1, RBL1, DNMT1, GATA4, CTNNA1, HIST1H1A, KDM5A, PHF1, CDYL, SETD8, JARID2 (tumor) | SUZ12, RBL2, USP7, CREB1, CDK8, CTCF, SIRT1, RBBP4, AEBP2, CEBPD, MED17, RB1, RBL1, DNMT1, PPP1R8, CTNNA1, KDM5A, PHF1, MTF2, CDYL, JARID2 (normal) |
 |  |
| STAD (tumor) | STAD (normal) |
| SUZ12, ELAVL1, E2F1, RBL2, USP7, CREB1, RBBP7, SIRT1, RBBP4, AEBP2, CBX5, MED17, RB1, HIST1H1C, GATA4, CDK19, EED, WT1, CDYL, EZH1, H2AFY2 (tumor) | SUZ12, E2F1, RELB, SETDB1, HDAC2, USP7, CTCF, EWSR1, PML, SIRT1, RBBP4, EZH2, CEBPD, RBL1, DNMT1, CDK19, UHRF1, EED, HIC1, PHF1, MTF2 (normal) |
 |  |
| THCA (tumor) | THCA (normal) |
| SUZ12, RBL2, USP7, CREB1, CDK8, CTCF, UBE2I, SIRT1, RBBP4, AEBP2, MED17, RB1, RBL1, HIST1H1C, DNMT1, CDK19, KDM5A, PHF1, MTF2, CDYL, H2AFY2 (tumor) | SUZ12, SUMO2, RBL2, USP7, CREB1, CDK8, CTCF, EWSR1, PML, SIRT1, RBBP4, AEBP2, CBX5, RB1, RBL1, HIST1H1C, CDK19, KDM5A, PHF1, CDYL, H2AFY2 (normal) |
 |  |
| Top |
| TissGeneProg for SUZ12 |
| Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
 |
| Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Top |
| TissGeneClin for SUZ12 |
| TissGeneDrug for SUZ12 |
| Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
| DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Top |
| TissGeneDisease for SUZ12 |
| Disease information associated with TissGene (DisGeNet, 2016-06-01) |
| Disease ID | Disease name | # pubmeds | Source |
| umls:C0206630 | Endometrial Stromal Sarcoma | 13 | BeFree,ORPHANET |
| umls:C0334695 | Endometrial Stromal Tumors | 6 | BeFree,LHGDN |
| umls:C0027627 | Neoplasm Metastasis | 5 | BeFree |
| umls:C0699791 | Stomach Carcinoma | 4 | BeFree |
| umls:C0006142 | Malignant neoplasm of breast | 2 | BeFree |
| umls:C0009402 | Colorectal Carcinoma | 2 | BeFree |
| umls:C0017636 | Glioblastoma | 2 | BeFree,CTD_human |
| umls:C0017638 | Glioma | 2 | BeFree,CTD_human |
| umls:C0019163 | Hepatitis B | 2 | BeFree |
| umls:C0023467 | Leukemia, Myelocytic, Acute | 2 | BeFree |
| umls:C0023903 | Liver neoplasms | 2 | BeFree |
| umls:C0024623 | Malignant neoplasm of stomach | 2 | BeFree |
| umls:C0025202 | melanoma | 2 | BeFree,CTD_human |
| umls:C0027830 | neurofibroma | 2 | BeFree,CTD_human |
| umls:C0178874 | Tumor Progression | 2 | BeFree |
| umls:C0206727 | Nerve Sheath Tumors | 2 | BeFree,CTD_human |
| umls:C0206728 | Plexiform Neurofibroma | 2 | BeFree |
| umls:C0376358 | Malignant neoplasm of prostate | 2 | BeFree |
| umls:C0596263 | Carcinogenesis | 2 | BeFree |
| umls:C0600139 | Prostate carcinoma | 2 | BeFree |
| umls:C0677886 | Epithelial ovarian cancer | 2 | BeFree |
| umls:C0678222 | Breast Carcinoma | 2 | BeFree |
| umls:C0686619 | Secondary malignant neoplasm of lymph node | 2 | BeFree |
| umls:C0751690 | Malignant Peripheral Nerve Sheath Tumor | 2 | BeFree |
| umls:C1527249 | Colorectal Cancer | 2 | BeFree |
| umls:C0001430 | Adenoma | 1 | CTD_human |
| umls:C0005684 | Malignant neoplasm of urinary bladder | 1 | BeFree |
| umls:C0006118 | Brain Neoplasms | 1 | BeFree |
| umls:C0007102 | Malignant tumor of colon | 1 | BeFree |
| umls:C0007103 | Malignant neoplasm of endometrium | 1 | BeFree |
| umls:C0007131 | Non-Small Cell Lung Carcinoma | 1 | BeFree |
| umls:C0007847 | Malignant tumor of cervix | 1 | BeFree |
| umls:C0014170 | Endometrial Neoplasms | 1 | CTD_human |
| umls:C0023473 | Myeloid Leukemia, Chronic | 1 | BeFree |
| umls:C0024301 | Lymphoma, Follicular | 1 | BeFree |
| umls:C0027809 | Neurilemmoma | 1 | CTD_human |
| umls:C0027831 | Neurofibromatosis 1 | 1 | BeFree,LHGDN |
| umls:C0027962 | Melanocytic nevus | 1 | CTD_human |
| umls:C0033027 | Preleukemia | 1 | BeFree |
| umls:C0038356 | Stomach Neoplasms | 1 | BeFree |
| umls:C0080178 | Spina Bifida | 1 | RGD |
| umls:C0279000 | Liver and Intrahepatic Biliary Tract Carcinoma | 1 | BeFree |
| umls:C0302592 | Cervix carcinoma | 1 | BeFree |
| umls:C0334485 | Endometrial stromal nodule | 1 | BeFree |
| umls:C0334486 | Low Grade Endometrial Stromal Sarcoma | 1 | BeFree |
| umls:C0334634 | Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse | 1 | BeFree |
| umls:C0345904 | Malignant neoplasm of liver | 1 | BeFree |
| umls:C0346429 | Multiple malignancy | 1 | BeFree |
| umls:C0476089 | Endometrial Carcinoma | 1 | BeFree |
| umls:C0553580 | Ewings sarcoma | 1 | BeFree |
| umls:C0598766 | Leukemogenesis | 1 | BeFree |
| umls:C0699790 | Colon Carcinoma | 1 | BeFree |
| umls:C0699885 | Carcinoma of bladder | 1 | BeFree |
| umls:C0936223 | Metastatic Prostate Carcinoma | 1 | BeFree |
| umls:C1458155 | Mammary Neoplasms | 1 | BeFree |
| umls:C1883486 | Uterine Corpus Cancer | 1 | BeFree |
| umls:C2239176 | Liver carcinoma | 1 | BeFree |
| umls:C2239246 | Endometrial stromal sarcoma, high grade | 1 | BeFree |
| umls:C2745900 | Promyelocytic leukemia | 1 | BeFree |
| umls:C3463824 | MYELODYSPLASTIC SYNDROME | 1 | BeFree |
Copyright 2016-Present - The University of Texas Health Science Center at Houston (UTHealth) Web File Viewing | How to Report, Fraud, Waste and Abuse | State of Texas | Statewide Search | Texas Homeland Security | Site Policies |